PHT Corporation VP of Clinical Science and Consulting Services Dr. Susan Dallabrida Named to the PharmaVOICE 100

PHT Corporation's picture
Printer-friendly versionPrinter-friendly version

Dr. Dallabrida chosen for innovating technologies to improve eClinical research that collects patient-driven eData

August 13, 2014

BOSTON, Mass. and GENEVA, Switzerland – announced Vice President of Clinical Science and Consulting Susan Dallabrida, PhD, is among this year’s PharmaVOICE 100 most inspiring professionals in the life sciences industries. Dr. Dallabrida is the 6th PHT executive to earn a place on the list. PHT is the leading provider of technologies used to collect patient-driven eData  for clinical research. 


Read the PharmaVOICE article on how Dr. Dallabrida is “Orchestrating Science & Technology” at PHT:


Established 10 years ago by PharmaVOICE magazine, the PharmaVOICE 100 is an annual list of individuals recognized for their positive contributions to the industry. Susan Dallabrida was chosen for her world-class scientific expertise in offering the pharma, biotech and life sciences industries a combination of vision and practicality in using eClinical technologies that drive efficiencies within pragmatic research.  


PHT President and CEO Philip Lee, who was a 2011 PharmaVOICE 100 honoree, said, “Susan has a well-earned reputation for leadership in developing technologies to provide evidence, data analysis and creative solutions that result in huge improvements in study design that is focused on the patient. We congratulate her on this well-earned recognition from her peers.


Susan Dallabrida has over 21 years of experience as a senior scientist, consultant and leader in clinical research and development, trial design and strategy, and product development. She has significant regulatory experience for biologics and small molecules. Susan has led cross-functional drug discovery and product development teams and collaborations in therapeutic areas including oncology, cardiovascular disease, hemophilia, dermatology, obesity, and vascular disorders. She has a broad background in scientific presentations and writing with 21 publications, 14 grants, 3 patents, 18 awards, 43 conference presentations, and 29 abstracts.


Susan said, “It’s a great honor to be among my industry colleagues on the PharmaVOICE 100.  We all share a responsibility to lead initiatives with the ultimate goal of accelerating the development and launch of effective and safe therapies, and incorporating technologies into clinical care to improve health care and quality of life for patients.”

About PHT Corporation

PHT Corporation is the eClinical innovator leading the adoption of patient-driven mobile apps for better clinical research. The PHT electronic clinical outcome assessment (eCOA) system collects and reports secure real-time patient data from the latest mobile devices. PHT scientific, regulatory and technological expertise combined with quality outcomes data enable clients to make research decisions with confidence. Sponsors and CROs have leveraged the PHT Patient Suite in 650+ trials resulting in 17+ regulatory approvals

Copy this html code to your website/blog to embed this press release.


Post new comment

6 + 9 =

To prevent automated spam submissions leave this field empty.